NCT07154511View on ClinicalTrials.gov

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Parkinson DiseaseParkinson Disease Dementia
Interventions
DRUG

Tributyrin

Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

DRUG

Placebo

Participants will take 500mg TID placebo for 90 days +/- 7 days.

Trial Locations (1)

48105

RECRUITING

Domino's Farms, Ann Arbor

All Listed Sponsors
collaborator

Farmer Family Foundation

UNKNOWN

lead

Prabesh Kanel

OTHER

NCT07154511 - Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments | Biotech Hunter | Biotech Hunter